Dr Vazrick Navasartian, DDS | |
24863 W. Hayne Ave, Coaling, CA 93210 | |
(559) 935-4900 | |
(559) 935-7021 |
Full Name | Dr Vazrick Navasartian |
---|---|
Gender | Male |
Speciality | Dentist |
Location | 24863 W. Hayne Ave, Coaling, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114101326 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
122300000X | Dentist | 50330 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Vazrick Navasartian, DDS 1756 E Quincy Ave, Fresno, CA 93720-2352 Ph: (559) 696-0595 | Dr Vazrick Navasartian, DDS 24863 W. Hayne Ave, Coaling, CA 93210 Ph: (559) 935-4900 |
News Archive
In Thursday night's debate, Vice President Joe Biden will almost certainly go after Representative Paul Ryan's Medicare plan. And why shouldn't he? It's unpopular. But I'd like to make a case for that plan. It's the best thing the Romney-Ryan campaign has going for it.
BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the first implantations of BIOTRONIK's new leadless cardiac monitoring device performed by a team of physicians led by Professor Dr. Gerhard Hindricks, Director, Electrophysiology Department at the Leipzig Heart Center in Leipzig, Germany.
Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for aesthetic treatments, is pleased to announce that the MaxG™ Optimized Pulsed Light™ (OPL) handpiece is now available worldwide for use on the company's StarLux® 500 and Artisan™ laser and pulsed light aesthetic systems.
To mark the International Year of Chemistry, the 94th Canadian Chemistry Conference and Exhibition will take place at the Palais des congr-s de Montr-al from June 5 to 9, 2011. The gathering is the biggest ever annual event in Canada to focus on science and the practice of chemistry.
Salix Pharmaceuticals, Ltd. has announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.
› Verified 5 days ago